Inhaltsbereich
| 35 Einträge | 1, 2 › » |
Seite 1 / 2
 Druckansicht
|
| Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. |
| Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart M, Hortobagyi GN, Eakle J, Mukai H, Iwata H, Geberth M, Hart LL, Hadji P, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl D, Campone M, Pritchard KI |
| Journal of the National Cancer Institute. 2013 Feb 19. pii: djt026. doi: 10.1093/jnci/djt026 |
| PMID: 23425564 |
| Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. |
| Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, Robert NJ, Silovski T, Gokmen E, von Minckwitz G, Ejlertsen B, Chia SK, Mansi J, Barrios CH, Gnant M, Buyse M, Gore I, Smith J, Harker G, Masuda N, Petrakova K, Zotano AG, Iannotti N, Rodriguez G, Tassone P, Wong A, Bryce R, Ye Y, Yao B, Martin M |
| The Lancet. Oncology. 2016 Feb 10. pii: S1470-2045(15)00551-3. doi: 10.1016/S1470-2045(15)00551-3 |
| PMID: 26874901 |
| Effects of everolimus (EVE) on disease progression in bone and bone markers (BMs) in patients (pts) with bone metastases (mets). |
| Baselga J, Rugo HS, Noguchi S, Pritchard KI, Burris HA, Piccart-Gebhart MJ, Eakle JF, Mukai H, Iwata H, El-Hashimy M, Rao S, Panneerselvam A, Taran T, Hortobagyi GN, Sahmoud T, Lebwohl DE, Gnant M |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Feb 1. doi: 10.1200/jco.2012.30.27_suppl.102 |
| PMID: 28146729 |
| Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial. |
| Martin M, Von Minckwitz G, Ejlertsen B, Chia SK, Buyse ME, Mansi J, Gnant M, Holmes FA, Moy B, Iwata H, Wong A, Lalani AS, Bryce R, Bebchuk JD, Delaloge S |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Feb 2. doi: 10.1200/jco.2015.33.28_suppl.117 |
| PMID: 28147820 |
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. |
| Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A |
| The Lancet. Oncology. 2017 Nov 13. pii: S1470-2045(17)30717-9. doi: 10.1016/S1470-2045(17)30717-9 |
| PMID: 29146401 |
| Effects of Neratinib on Health-Related Quality-of-Life in Women with HER2-Positive Early-Stage Breast Cancer: Longitudinal Analyses from the Randomized Phase III ExteNET Trial. |
| Delaloge S, Cella D, Ye Y, Buyse M, Chan A, Barrios CH, Holmes FA, Mansi J, Iwata H, Ejlertsen B, Moy B, Chia SKL, Gnant M, Smichkoska S, Ciceniene A, Martinez N, Filipovic S, Ben-Baruch NE, Joy AA, Langkjer ST, Senecal F, de Boer RH, Moran S, Yao B, Bryce R, Auerbach A, Fallowfield L, Martin M |
| Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Jan 23. pii: 5299438. doi: 10.1093/annonc/mdz016 |
| PMID: 30689703 |
| PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial. |
| Chia SKL, Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Kim SB, Jakobsen EH, Harvey V, Robert N, Smith J, Harker G, Zhang B, Eli LD, Ye Y, Lalani AS, Buyse M, Chan A |
| Breast cancer research : BCR. 2019 Mar 11. doi: 10.1186/s13058-019-1115-2. pii: 10.1186/s13058-019-1115-2 |
| PMID: 30867034 |
| Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial. |
| Delaloge S, Cella D, Ye Y, Buyse M, Chan A, Barrios CH, Holmes FA, Mansi J, Iwata H, Ejlertsen B, Moy B, Chia SKL, Gnant M, Smichkoska S, Ciceniene A, Martinez N, Filipović S, Ben-Baruch NE, Joy AA, Langkjer ST, Senecal F, de Boer RH, Moran S, Yao B, Bryce R, Auerbach A, Fallowfield L, Martin M |
| Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Dec 4. pii: S0923-7534(19)31112-3. doi: 10.1093/annonc/mdz016 |
| PMID: 31987273 |
| Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. |
| Chan A, Moy B, Mansi J, Ejlertsen B, Holmes FA, Chia S, Iwata H, Gnant M, Loibl S, Barrios CH, Somali I, Smichkoska S, Martinez N, Alonso MG, Link JS, Mayer IA, Cold S, Murillo SM, Senecal F, Inoue K, Ruiz-Borrego M, Hui R, Denduluri N, Patt D, Rugo HS, Johnston SRD, Bryce R, Zhang B, Xu F, Wong A, Martin M |
| Clinical breast cancer. 2020 Oct 6. pii: S1526-8209(20)30258-5. doi: 10.1016/j.clbc.2020.09.014 |
| PMID: 33183970 |
| Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). |
| Mayer EL, Fesl C, Hlauschek D, Garcia-Estevez L, Burstein HJ, Zdenkowski N, Wette V, Miller KD, Balic M, Mayer IA, Cameron D, Winer EP, Ponce Lorenzo JJ, Lake D, Pristauz-Telsnigg G, Haddad TC, Shepherd L, Iwata H, Goetz M, Cardoso F, Traina TA, Sabanathan D, Breitenstein U, Ackerl K, Metzger Filho O, Zehetner K, Solomon K, El-Abed S, Theall KP, Lu DR, Dueck A, Gnant M, DeMichele A |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Jan 7. doi: 10.1200/JCO.21.01918 |
| PMID: 34995105 |
| A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. |
| Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED, Ngan Y, Petersen LK, Lazcano-Ponce E, Pitisuttithum P, Restrepo JA, Stuart G, Woelber L, Yang YC, Cuzick J, Garland SM, Huh W, Kjaer SK, Bautista OM, Chan IS, Chen J, Gesser R, Moeller E, Ritter M, Vuocolo S, Luxembourg A |
| The New England journal of medicine. 2015 Feb 19. doi: 10.1056/NEJMoa1405044 |
| PMID: 25693011 |
| Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer. |
| Kimura S, D' Andrea D, Soria F, Foerster B, Abufaraj M, Vartolomei MD, Iwata T, Karakiewicz PI, Rink M, Gust KM, Egawa S, Shariat SF |
| Urologic oncology. 2018 Dec 20. pii: S1078-1439(18)30451-4. doi: 10.1016/j.urolonc.2018.11.005 |
| PMID: 30580906 |
| Perioperative blood transfusion affects oncologic outcomes after nephrectomy for renal cell carcinoma: A systematic review and meta-analysis. |
| Iwata T, Kimura S, Foerster B, Abufaraj M, Karakiewicz PI, Preisser F, Nasu Y, Shariat SF |
| Urologic oncology. 2019 Feb 5. pii: S1078-1439(19)30019-5. doi: 10.1016/j.urolonc.2019.01.018 |
| PMID: 30737159 |
| Focal Neuroendocrine Differentiation of Conventional Prostate Adenocarcinoma as a Prognostic Factor after Radical Prostatectomy: A Systematic Review and Meta-Analysis. |
| Kardoust Parizi M, Iwata T, Kimura S, Janisch F, Abufaraj M, Karakiewicz PI, Enikeev D, Rapoport LM, Hutterer G, Shariat SF |
| International journal of molecular sciences. 2019 Mar 19. pii: ijms20061374. doi: 10.3390/ijms20061374 |
| PMID: 30893781 |
| Oncologic outcomes after robot-assisted versus open radical cystectomy: a systematic review and meta-analysis. |
| Iwata T, Kimura S, Foerster B, Fossati N, Briganti A, Karakiewicz PI, Gust KM, Egawa S, Nasu Y, Abufaraj M, Shariat SF |
| World journal of urology. 2019 Apr 11. doi: 10.1007/s00345-019-02708-8. pii: 10.1007/s00345-019-02708-8 |
| PMID: 30976902 |
| Performance of [Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection: a systematic review and meta-analysis. |
| Kimura S, Abufaraj M, Janisch F, Iwata T, Parizi MK, Foerster B, Fossati N, Briganti A, Egawa S, Hartenbach M, Shariat SF |
| Prostate cancer and prostatic diseases. 2019 May 30. doi: 10.1038/s41391-019-0156-z. pii: 10.1038/s41391-019-0156-z |
| PMID: 31147628 |
| Impact of alcohol consumption on the risk of developing bladder cancer: a systematic review and meta-analysis. |
| Vartolomei MD, Iwata T, Roth B, Kimura S, Mathieu R, Ferro M, Shariat SF, Seitz C |
| World journal of urology. 2019 Jun 6. doi: 10.1007/s00345-019-02825-4. pii: 10.1007/s00345-019-02825-4 |
| PMID: 31172281 |
| Prognostic role of the urokinase plasminogen activator (uPA) system in patients with nonmuscle invasive bladder cancer. |
| Iwata T, Kimura S, Abufaraj M, Janisch F, Parizi MK, Haitel A, Rink M, Rouprêt M, Fajkovic H, Seebacher V, Nyirady P, Karakiewicz PI, Enikeev D, Rapoport LM, Nasu Y, Shariat SF |
| Urologic oncology. 2019 Jun 26. pii: S1078-1439(19)30219-4. doi: 10.1016/j.urolonc.2019.05.019 |
| PMID: 31255543 |
| The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: A systematic review. |
| Iwata T, Kimura S, Abufaraj M, Janisch F, Karakiewicz PI, Seebacher V, Rouprêt M, Nasu Y, Shariat SF |
| Urologic oncology. 2019 Jun 26. pii: S1078-1439(19)30221-2. doi: 10.1016/j.urolonc.2019.05.021 |
| PMID: 31255542 |
| Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review and meta-analysis. |
| Kardoust Parizi M, Abufaraj M, Fajkovic H, Kimura S, Iwata T, D'Andrea D, Karakiewicz PI, Shariat SF |
| Urologic oncology. 2019 Jul 8. pii: S1078-1439(19)30236-4. doi: 10.1016/j.urolonc.2019.06.007 |
| PMID: 31296421 |
| 35 Einträge | 1, 2 › » |
Seite 1 / 2
Druckansicht
|
Schnellinfo
-- Initiative Krebsforschung / Krebsforschungslauf
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
